## EXAS: Exact Sciences Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.8% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0); RSI 82 overbought. Stock is in no-man's land without clear edge. Caution: declining volume (32% of avg), overbought RSI (82).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($99.90)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Exact Sciences Corp.: Turning DNA Into a Weapon Against Cancer**
- Source: AD HOC NEWS | 20251231T130849 | Bullish | Relevance: 100%
- Exact Sciences Corp. is revolutionizing cancer detection through non-invasive, DNA-driven tests like Cologuard and Oncotype. The company focuses on early cancer detection, challenging traditional methods by offering consumer-grade usability paired with rigorous genomics. Its strategy involves continuous innovation, expanding beyond current flagship products into multi-cancer early detection and minimal residual disease monitoring, aiming to solidify its market position against competitors.

**2. Exact Sciences Stock Is Going Wild: Is This Cancer-Test Giant a Hidden Gem or Total Trap?**
- Source: AD HOC NEWS | 20260101T220904 | Neutral | Relevance: 100%
- Exact Sciences Corporation (EXAS) is gaining significant attention for its cancer screening technology, particularly an at-home colon cancer test. The article examines whether the company is a promising growth opportunity or a risky investment, highlighting its legitimate product, real but not yet consistently profitable revenue, and significant stock price volatility. Investors are advised to consider their risk tolerance and long-term outlook before making a decision on this high-risk, high-potential bet in the healthcare sector.

**3. Smart Oncology: 5 Stocks Chasing the $317B Prize**
- Source: Morningstar | 20251231T120849 | Bullish | Relevance: 100%
- The precision oncology market is rapidly expanding, driven by advancements in biomarker-guided therapies and AI. This article highlights five key players—Oncolytics Biotech Inc., Exact Sciences Corp., Veracyte, Inc., Hologic, Inc., and Personalis, Inc.—that are at the forefront of this $317 billion industry. These companies are developing innovative solutions for cancer diagnosis and treatment, offering new hope for personalized and effective care.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($1.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- FMR, LLC: 9.8% (-30.6%)
- Vanguard Group Inc: 9.4% (-0.5%)
- Capital World Invest: 8.5% (-11.3%)
- Blackrock Inc.: 5.6% (+0.3%)
- Wellington Managemen: 2.8% (-55.6%)

### Key Risks

1. Volume divergence: price rising (+1.6% MRS) on declining volume (32% of avg) suggests distribution.
2. Overbought RSI (82) with bearish MACD signals exhaustion.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.6% over 5 days suggests accumulation.

### Fundamentals

Forward P/E 91.0x attractive for 231% earnings growth. Balance sheet: strong liquidity (2.7x). Insider selling cluster ($1.7M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.3B |
| Beta | 1.42 |
| 52W Range | $38.81 - $102.66 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.07 |
| Forward P/E | 91.0 |
| Current P/E | 300.9 |
| YoY Growth | 230.6% |
| EPS Direction | FALLING |

### Technicals

MRS_20 strengthening from -0.8% to 0.8% (+1.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.2pp (needs >4.0% for momentum thesis). MRS_5 at 0.7% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.20), momentum weakening. RSI overbought at 82, risk of mean reversion. Volume at 32% of 20MA suggests lack of conviction. OFD pattern: +DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.78% (CS: 50) | Neutral |
| RSI_14 | 82.0 | Overbought |
| MACD Histogram | -1.20 | Bearish |
| vs SMA20 | 1.002x | Above |
| vs SMA50 | 1.169x | Above |
| vs SMA200 | 1.697x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.74
- **Stop Loss:** $99.90 (1.8% risk)
- **Target:** $103.58 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 782
- **Position Value:** $79,560.68
- **Portfolio %:** 79.56%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-25 (Est: $0.08)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.16 | $0.24 | +49.5% |
| 2025Q2 | $0.05 | $0.10 | +84.9% |
| 2025Q1 | $-0.10 | $-0.36 | -276.9% |
| 2024Q4 | $-0.19 | $-0.06 | +67.9% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*